Type 1 diabetes patients using MiniMed’s Smart Multiple Daily Injection (MDI) system who responded to more missed-dose and high-glucose alerts had, on average, 8.1 percentage points more time in range (TIR) and 0.6 percentage points lower HbA1c than lower responders, results from a six-month trial have revealed.
MiniMed’s Smart MDI system connects the InPen smart insulin pen with a continuous glucose monitor through the MiniMed Go app. This smart pen system tracks doses, provides dose calculations, and sends missed-dose and high-glucose alerts alongside glucose insights. MiniMed highlighted that Smart MDI, which secured US Food and Drug Administration (FDA) approval in January 2026, brings these functions into one app, instead of asking people to coordinate a pen, glucose monitor, and dosing decisions separately.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In the six-month randomised controlled trial of 143 type 1 diabetes patients, users with a higher response rate to alerts achieved, on average, 8.1 percentage points higher TIR and 0.6 percentage points lower HbA1c compared with lower responders.
Meanwhile, additional real-world analysis of more than 5,500 users found a 9.4 percentage-point difference in TIR between higher and lower responders.
The findings were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), which took place in Milan, Italy, from 28 September to 2 October.
Professor Laurent Crenier, study lead and head of the endocrinology department at HUB – Hôpital Erasme in Brussels, Belgium, commented: “These findings show a clear association between responding to Smart MDI alerts and better glucose outcomes. For people on multiple daily injections, that can mean more time in range with less day-to-day mental burden.”
Dexcom was among other companies in the diabetes space that presented at EASD 2026. The continuous glucose monitor (CGM) specialist presented findings from a report,
MiniMed was formerly operated as Medtronic’s Diabetes business but separated from the company and completed a $560m initial public offering (IPO), seeing it listed on the Nasdaq exchange, in March 2026. Medtronic, in recognition of MiniMed as an independent entity, launched an exchange offer, permitting Medtronic shareholders to exchange their Medtronic ordinary shares for shares of MiniMed common stock at a 7% discount, in September.
